Combination Drug Targets Core Pathologies of ALS Parkinson's and Alzheimer's with Alon Ben-Noon NeuroSense Therapeutics

Alon Ben-Noon, CEO and board member of NeuroSense Therapeutics, is taking a unique approach to treating neurodegenerative diseases by targeting core pathologies and combining molecules to address various mechanisms. NeuroSense has seen positive clinical trial results for ALS using their lead compound PrimeC, which showed a reduction in disease progression. Research indicates the potential for this approach to be applied to other neurodegenerative diseases like Alzheimer's and Parkinson's.   Alon explains, "The main challenge is to find a therapeutic asset for a complex disease, which is still not understood well enough to date. ALS, also Alzheimer's, and I think that Parkinson's is among them as well. All of those neurodegenerative diseases are very complex and involve many mechanisms that go wrong. We try to tackle them with the therapeutic agents while we are not certain with each patient what exactly goes on. This is a huge challenge, so we need to be creative and find ways how we may be able to provide benefits to the majority of the patients, and I should be more distinct to say a benefit to some extent." "In order to maximize the success with our therapy, we figured out that we need to target more than just one single mechanism and we need to tackle as much as we can or as many as we can. And looking at the more pertinent targets in our view and our understanding, we combine two molecules that target several mechanisms in a synergistic manner. We found molecules that can target these pathological pathways that were identified from the start. Also, it was important for us to see that they can work synergistically together on these targets." #NeuroSense #ALS #Parkinsons #Alzheimers #NeurodegenerativeDiseases NeuroSense-TX.com Download the transcript here